Q-omics provides the consensus-scored LRRC52 profile across patient tissues and cancer cell-line models. LRRC52 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LRRC52 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, LRRC52 RNA expression shows 6,960 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UVM, KIRC, and STAD as cancer lineages where LRRC52 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC52 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC52 survival associations across molecular data types. LRRC52 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC52 RNA expression–survival associations across cancer types. High LRRC52 expression shows unfavorable associations in UVM, COAD, UCEC, LUSC and ACC, but favorable associations in OV. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for LRRC52 RNA expression.
This table summarizes LRRC52 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LRRC52. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC52 shows lower tumor expression in KIRC, KIRP, COAD and LUSC and higher tumor expression in THCA and UCEC. The KIRC box plot shows higher LRRC52 RNA expression in normal versus tumor tissue (log2 FC = −1.214, t-test p < 0.001).
This table shows molecular features associated with LRRC52 in patient tissues and cancer cell lines. In patient samples, LRRC52 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC52 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SKIN.
